Transthyretin Amyloidosis Treatment Market Trends

• Advancements in diagnostic techniques has significantly contributed to the market growth. With the development of more sensitive imaging modalities such as cardiac MRI and nuclear scintigraphy, along with improved genetic testing methods, early and accurate diagnosis has become more achievable.
  
• For instance, recent advancements in nuclear cardiac imaging with technetium pyrophosphate scan, the diagnosis of ATTR-CM is possible without cardiac biopsy. Therefore, more patients are being screened and diagnosed with ATTR-CM.
  
• These advancements not only facilitate timely treatment initiation but also enable better patient management and monitoring. Additionally, the introduction of novel biomarkers and the ongoing research into new diagnostic technologies promise further improvements in the diagnosis and management of transthyretin amyloidosis, propelling the market growth, and in turn propelling the rare disease treatment market as well.